{"id":"W3170480273","doi":"10.1200/jco.2021.39.15_suppl.tps9596","title":"Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Ipilimumab; Nivolumab; Melanoma; Oncology; Internal medicine; Regimen; Immunotherapy; Targeted therapy; Vemurafenib; Cancer research; Metastatic melanoma; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001733126,0.001668399,0.001467776,0.0003290962,0.0004211122,0.001058214,0.0008779551,0.001270739,0.00451385],"category_scores_gemma":[0.0007100404,0.0006755901,0.00129785,0.0003709578,0.0009020288,0.0010433,0.0003354961,0.002879407,0.0008682453],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001280944,"about_ca_system_score_gemma":0.001329652,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001921586,"about_ca_topic_score_gemma":0.005290739,"domain_scores_codex":[0.9996203,0.0001766747,0.00001521316,0.00006990756,0.00002949629,0.0000882224],"domain_scores_gemma":[0.9994276,0.00006883043,0.0001034036,0.00004118693,0.00003264782,0.0003263271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9098529,0.02882721,0.003058882,0.0004653474,0.001229881,0.0001284131,0.0001245172,0.001318259,0.01605277,0.0001988601,0.003053127,0.03568988],"study_design_scores_gemma":[0.7350559,0.25047,0.008841935,0.0000322212,0.0004307526,0.0002018251,0.00006119631,0.0007767283,0.001679435,0.0001695811,0.002255026,0.00002546018],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989457,0.00299533,0.0004472462,0.0007041144,0.0002624858,0.001974522,0.001817404,0.0001019459,0.002239999],"genre_scores_gemma":[0.9862338,0.001976123,0.001461736,0.0008679067,0.000174164,0.001994085,0.002936979,0.00003430546,0.00432095],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00451385,"threshold_uncertainty_score":0.01510036,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04627741315498596,"score_gpt":0.3880112685749552,"score_spread":0.3417338554199693,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}